Dean Kirkel

Statistics

Publications

Citations

653

H-Index

Active since

2009

Affiliations

National Hospital Organization(Current)

Oslo University Hospital

Clinica Universidad de Navarra

Institut Català d'Oncologia

University of Oslo

Dean Kirkel is an author at National Hospital Organization specializing in medicine, relapsed multiple myeloma, and hematologic malignancy pharmacotherapy.

Publications per year

2009–2019

Publications

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 385 citations · Full text

Medicine, Hematology, Pharmacotherapy +11

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold et al. · The Lancet Haematology · 2019 · 253 citations · Full text

Medicine, Oncology, Pharmacology +12

Asymptomatic factor VII deficiency: gene analysis and structure–function relationships

Dean Kirkel, Ta-Wei Lin, Sidney W. Fu et al. · Blood Coagulation & Fibrinolysis · 2009 · 15 citations

Medicine, Genetics, Molecular Genetics +14

1–3 of 3